EcoDrugPlus

Tyrosine-Protein Phosphatase Non-Receptor Type 11

Ensembl ID : ENSSFOG00015017592
Gene Symbol: LOC108936064
3 Cross references
249 Possible Orthologues:

Tyrosine-Protein Phosphatase Non-Receptor Type 11-Like

Ensembl ID : ENSSFOG00015017943
Gene Symbol: LOC108934731
3 Cross references
249 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSSFOG00015000850
Gene Symbol: LOC108930839
3 Cross references
301 Possible Orthologues:

Uncharacterized Loc108928799

Ensembl ID : ENSSFOG00015008563
Gene Symbol: LOC108928799
2 Cross references
196 Possible Orthologues:

Utrophin

Ensembl ID : ENSSFOG00015015814
Gene Symbol: UTRN
1 Cross references
103 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSSFOG00015021380
Gene Symbol: RELA
1 Cross references
199 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSSFOG00015032179
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor Receptor 1

Ensembl ID : ENSSFOG00015015683
Gene Symbol: LOC108939599
3 Cross references
198 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSSFOG00015016387
Gene Symbol: VDR
3 Cross references
457 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSSFOG00015018685
Gene Symbol: VDR
3 Cross references
457 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSSFOG00015024706
Gene Symbol: LOC108941679
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSSFOG00015005549
Gene Symbol: LOC108936607
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).